Key result
NRG1 administration shows therapeutic promise for myocardial injury and heart failure via ErbB4 signaling.
Why the study?
The NRG1/ErbB4 receptor signaling pathway plays a critical role in cardiovascular development, vascular biology, and cardiac injury.
This review highlights the potential therapeutic value of targeting the NRG1/ErbB4 signaling pathway for myocardial injury and heart failure.
Answers are grounded in this paper and cite their sources.
NRG1/ErbB4 targeting merits further study in myocardial injury; hypothesis-generating and should not yet change practice.
The NRG1/ErbB4 receptor signaling pathway plays a critical role in the regulation of cardiovascular development, vascular biology, and cardiac injury. This review provides an overview of the NRG/ErbB receptor signaling pathway and its involvement in the regulation of cardiac development, vascular biology, and cardiac injury. We discuss the regulation of NRG on vascular biology and vascular regeneration, the endogenous activation of NRG1/ErbB receptor signaling pathway in alleviating myocardial ischemic injury, and the potential therapeutic value of NRG1 on myocardial injury and heart failure.
No takes yet. Share an insight, caveat, or question.
Anbiao Wang (2023) conducted a review in Cardiovascular disease, myocardial injury, heart failure. NRG1 was evaluated. The NRG1/ErbB4 receptor signaling pathway regulates cardiovascular development and cardiac function, and NRG1 administration demonstrates potential therapeutic value for treating myocardial injury and heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: